Term
Alkylating Agents
Nitrogen Mustards |
|
Definition
Cyclophosphamide (Cytoxan®)
Ifosfamide (Ifex®)
Mechlorethamine (Mustargen®)
Melphalan (Alkeran®)
Chlorambucil (Leukeran®)
Estramustine (Emcyt®)
MOA: Alkylates and crosslinks DNA |
|
|
Term
|
Definition
Cytoxan®
Nitrogen Mustard (Alkylating Agent) |
|
|
Term
|
Definition
Ifex®
Nitrogen Mustard (Alkylating Agent) |
|
|
Term
|
Definition
Mustargen®
Nitrogen Mustard (Alkylating Agent) |
|
|
Term
|
Definition
Alkeran®
Nitrogen Mustard (Alkylating Agent) |
|
|
Term
|
Definition
Leukeran®
Nitrogen Mustard (Alkylating Agent) |
|
|
Term
|
Definition
Emcyt®
Nitrogen Mustard (Alkylating Agent) |
|
|
Term
Alkylating Agents
Nitrosoureas |
|
Definition
Carmustine (BiCNU®)
Lomustine (CeeNU®)
Streptozocin (Zanosar®)
MOA: Alkylates and crosslinks DNA |
|
|
Term
|
Definition
BiCNU®
Nitrosourea (Alkylating Agent) |
|
|
Term
|
Definition
CeeNU®
Nitrosourea (Alkylating Agent) |
|
|
Term
|
Definition
Zanosar®
Nitrosourea (Alkylating Agent) |
|
|
Term
Alkylating Agents
Platinum Analogs |
|
Definition
Cisplatin (Platinol®)
Carboplatin (Paraplatin®)
Oxaliplatin (Eloxatin®)
MOA: Binds and crosslinks DNA |
|
|
Term
|
Definition
Platinol®
Platinum Analog (Alkylating Agent) |
|
|
Term
|
Definition
Paraplatin®
Platinum Analog (Alkylating Agent) |
|
|
Term
|
Definition
Eloxatin®
Platinum Analog (Alkylating Agent) |
|
|
Term
|
Definition
Busulfan (Myleran®)
Thiotepa
Procarbazine (Matulane®)
Dacarbazine (DTIC-Dome®)
Temozolomide (Temodar®)
MOA: Binds and crosslinks DNA |
|
|
Term
|
Definition
Myleran®
Other (Alkylating Agent) |
|
|
Term
|
Definition
No Brand Name
Other (Alkylating Agent) |
|
|
Term
|
Definition
Matulane®
Other (Alkylating Agent) |
|
|
Term
|
Definition
DTIC-Dome®
Other (Alkylating Agent) |
|
|
Term
|
Definition
Temodar®
Other (Alkylating Agent) |
|
|
Term
Antimetabolites
Folate Analogs |
|
Definition
Methotrexate (Rheumatrex®)
Pemetrexed (Alimta®)
MOA: Inhibits dihydrofolate reductase and lymphocyte proliferation |
|
|
Term
|
Definition
Rhematrex®, Trexall®
Folate Analog (Antimetabolite) |
|
|
Term
|
Definition
Alimta®
Folate Analog (Antimetabolite) |
|
|
Term
Antimetabolites
Pyrimidine Analogs |
|
Definition
5-Fluorouracil (Efudex®)
Cytarabine (Cytosar-C®)
Gemcitabine (Gemzar®)
Capecitabine (Xeloda®)
Azacitidine (Vidaza®)
MOA: Inhibits DNA and RNA synthesis |
|
|
Term
|
Definition
Efudex®, Adrucil®
Pyrimidine Analog (Antimetabolite) |
|
|
Term
|
Definition
Cytosar-C®, Ara-C
Pyrimidine Analog (Antimetabolite) |
|
|
Term
|
Definition
Gemzar®
Pyrimidine Analog (Antimetabolite) |
|
|
Term
|
Definition
Xeloda®
Pyrimidine Analog (Antimetabolite) |
|
|
Term
|
Definition
Vidaza®
Pyrimidine Analog (Antimetabolite) |
|
|
Term
Antimetabolites
Purine Analogs |
|
Definition
6-Mercaptopurine (Purinethol®)
6-Thioguanine (Tabloid®)
Fludarabine (Fludara®)
Cladribine (Leustatin®)
MOA: Inhibits DNA synthesis; Inhibits DNA polymerase alpha, DNA primase, and ribonucleotide reductase |
|
|
Term
|
Definition
Purinethol®
Purine Analog (Antimetabolite) |
|
|
Term
|
Definition
Tabloid®
Purine Analog (Antimetabolite) |
|
|
Term
|
Definition
Fludara®
Purine Analog (Antimetabolite) |
|
|
Term
|
Definition
Leustatin®
Purine Analog (Antimetabolite) |
|
|
Term
Mitosis Inhibitors
Vinca Alkaloids |
|
Definition
Vinblastine
Vincristine (Oncovin®)
Vinorelbine (Navelbine®)
MOA: Inhibits microtubule formation, arresting mitosis in metaphase |
|
|
Term
|
Definition
No Brand Name
Vinca Alkaloids (Mitosis Inhibitor) |
|
|
Term
|
Definition
Oncovin®, Vincasar® PFS
Vinca Alkaloid (Mitosis Inhibitor) |
|
|
Term
|
Definition
Navelbine®
Vinca Alkaloid (Mitosis Inhibitor) |
|
|
Term
Mitosis Inhibitors
Taxanes |
|
Definition
Paclitaxel (Taxol®)
Nab-paclitaxel (Abraxane®)
Docetaxel (Taxotere®)
Carbazitaxel (Jevtana®)
MOA: Promotes formation and inhibits disassembly of stable microtubules, inhibiting mitosis |
|
|
Term
|
Definition
Taxol®
Taxane (Mitosis Inhibitor) |
|
|
Term
|
Definition
Abraxane®
Taxane (Mitosis Inhibitor) |
|
|
Term
|
Definition
Taxotere®
Taxane (Mitosis Inhibitor) |
|
|
Term
|
Definition
Jevtana®
Taxane (Mitosis Inhibitor) |
|
|
Term
Mitosis Inhibitors
Topoisomerase Inhibitors |
|
Definition
Etoposide (Etopophos®)
Teniposide (Vumon®)
Irinotecan (Camptosar®)
MOA: Binds to topoisomerase I-DNA complexes, preventing religationof single-strand breaks |
|
|
Term
|
Definition
Etopophos®
Topoisomerase Inhibitor (Mitosis Inhibitor) |
|
|
Term
|
Definition
Vumon®
Topoisomerase Inhibitor (Mitosis Inhibitor) |
|
|
Term
|
Definition
Camptosar®
Topoisomerase Inhibitor (Mitosis Inhibitor) |
|
|
Term
|
Definition
Bleomycin (Blenoxane®)
Dactinomycin (Actinomycin-D®)
Mitomycin (Mutamycin®)
MOA: Inhibits DNA synthesis |
|
|
Term
|
Definition
Blenoxane®
Antitumor Antibiotic |
|
|
Term
|
Definition
Actinomycin D®, Cosmegen®
Antitumor Antibiotic |
|
|
Term
|
Definition
Mutamycin®
Antitumor Antibiotic |
|
|
Term
|
Definition
Doxorubucin (Adriamycin®)
Daunorubicin (Cerubidine®)
Idarubicin (Idamycin® PFS)
Epirubicin (Ellence®)
Valrubicin (Valstar®)
Mitoxantrone (Novantrone®)
MOA: Binds and intercalates into DNA, inhibiting nucleic acid and protein synthesis; triggers DNA cleavage by topoisomerase II |
|
|
Term
|
Definition
Adriamycin®
Anthracycline |
|
|
Term
|
Definition
Cerubidine®
Anthracycline |
|
|
Term
|
Definition
Idamycin® PFS
Anthracycline |
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
Novantrone®
Anthracycline |
|
|
Term
|
Definition
Tamoxifen (Soltamox®)
Anastrozole (Arimidex®)
Letrozole (Femara®)
MOA: Inhibits enzymatic androgen conversion to estrogen, reducing hormone receptor positive cancer cell growth |
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
Leuprolide (Lupron®)
Goserelin (Zoladex®)
MOA: Inhibits gonadotropin release, suppressing ovarian and testicular steroidogenesis |
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
Tyrosine Kinase Inhibitors |
|
Definition
Imatinib (Gleevec®)
Sorafenib (Nexavar®)
Vandetanib (Zactima®)
Pazopanib (Votrient®)
Gefitinib (Iressa®)
Erlontinib (Tarceva®)
Dasatinib (Sprycel®)
Nilotinib (Tasigna®)
Lapatinib (Tykerb®)
Sunitinib (Sutent®)
MOA: Inhibits intracellular tyrosine kinase domain of epidermal growth factor receptor (EGFR), resulting in cell cycle arrest and angiogenesis |
|
|
Term
|
Definition
Gleevec®
Tyrosine Kinase Inhibitor |
|
|
Term
|
Definition
Nexavar®
Tyrosine Kinase Inhibitor |
|
|
Term
|
Definition
Zactima®
Tyrosine Kinase Inhibitor |
|
|
Term
|
Definition
Votrient®
Tyrosine Kinase Inhibitor |
|
|
Term
|
Definition
Iressa®
Tyrosine Kinase Inhibitor |
|
|
Term
|
Definition
Tarceva®
Tyrosine Kinase Inhibitor |
|
|
Term
|
Definition
Sprycel®
Tyrosine Kinase Inhibitor |
|
|
Term
|
Definition
Tasigna®
Tyrosine Kinase Inhibitor |
|
|
Term
|
Definition
Tykerb®
Tyrosine Kinase Inhibitor |
|
|
Term
|
Definition
Sutent®
Tyrosine Kinase Inhibitor |
|
|
Term
|
Definition
Interferon alfa-2a (Roferon®)
Interferon alfa-2b (Intron A®)
Interferon alfa-n3 (Alferon-N®)
Aldesleukin (Proleukin®)
Denileukin difitox (Ontak®)
Bacillus Calmette-Guerin (BCG) |
|
|
Term
|
Definition
Roferon®
MOA: Inhibits cellular growth, alters the state of cellular differentiation, interferes with oncogene expression, alters cell surface antigen expression, increases phagocytic activity of macrophages and augments cytotoxicity of lymphocytes for target cells
Interferon (Immunotherapy) |
|
|
Term
|
Definition
Intron® A
MOA: Inhibits cellular growth, alters the state of cellular differentiation, interferes with oncogene expression, alters cell surface antigen expression, increases phagocytic activity of macrophages and augments cytotoxicity of lymphocytes for target cells
Interferon (Immunotherapy) |
|
|
Term
|
Definition
Alferon® N
MOA: Inhibits cellular growth, alters the state of cellular differentiation, interferes with oncogene expression, alters cell surface antigen expression, increases phagocytic activity of macrophages and augments cytotoxicity of lymphocytes for target cells
Interferon (Immunotherapy) |
|
|
Term
|
Definition
Proleukin®
MOA: Promotes proliferation, differentiation, and recruitment of T and B cells, natural killer cells, and thymocytes; causes cytolytic activity in a subset of lymphocytes and subsequent interactions stimulate the immune system and malignant cells; can stimulate lymphokine-activated killer (LAK) cells and tumor-infiltrating lymphocytes (TIL) cells
Immunotherapy |
|
|
Term
|
Definition
Ontak®
MOA: Binds to high affinity IL-2 receptors, inhibits protein synthesis, resulting in cell death
Immunotherapy |
|
|
Term
|
Definition
BCG
MOA: cross reacts with cytotoxic cells to cause destruction
Immunotherapy |
|
|
Term
|
Definition
Rituximab (Rituxan®)
Gentuzumab (Mylotarg®)
Bevacizumab (Avastin®)
Cetuximab (Erbitux®)
Trastuzumab (Herceptin®)
Ranibizumab (Lucentis®)
Panitumumab (Vectibix®)
MOA: Inhibits growth factor by binding to the outside of the cell |
|
|
Term
|
Definition
Rituxan®
Monoclonal Antibody |
|
|
Term
|
Definition
Mylotarg®
Monoclonal Antibody |
|
|
Term
|
Definition
Avastin®
Monoclonal Antibody |
|
|
Term
|
Definition
Erbitux®
Monoclonal Antibody |
|
|
Term
|
Definition
Herceptin®
Monoclonal Antibody |
|
|
Term
|
Definition
Lucentis®
Monoclonal Antibody |
|
|
Term
|
Definition
Vectibix®
Monoclonal Antibody |
|
|
Term
|
Definition
Chromic Phosphate
Sodium Phosphate P32
Sodium Iodide I131
Strontium 89 Chloride
Samarium SM 153 Lexidronam
None of these have brand names and he didn't state the mechanism of action |
|
|
Term
|
Definition
Hydroxyurea (Hydrea®)
Mitotane (Lysodren®)
Tretinoin (Retin-A®)
Alitretinoin (Panretin®)
|
|
|
Term
|
Definition
Hydrea®
MOA: Inhibits ribonucleotide diphosphate reductase
Miscellaneous Agents |
|
|
Term
|
Definition
Lysodren®
MOA: Supresses adrenal cotrex, modifies steroid metabolism
Miscellaneous Agent |
|
|
Term
|
Definition
Retin-A®
MOA: Induces differentiation and decreases proliferative of APL cells
Miscellaneous Agent |
|
|
Term
|
Definition
Parentin®
MOA: Binds to retionid receptors, inhibiting cell growth
Miscellaneous Agent |
|
|
Term
|
Definition
Sorangium cellulosum
Ixabepilone (Ixempra®)
MOA: Inhibits uritosis by the same mechanism as taxanes
|
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
Drugs to Treat Nausea and Vomiting |
|
Definition
Prochlorperazine (Compazine®)
Dronabinol (Marinol®)
Nabilone (Cesamet®)
Metoclopramide (Reglan®)
Ondansetron (Zofran®)
Granisetron (Kytril®)
Dolasetron (Anzemet®)
Palonsetron (Aloxi®)
Aprepitant (Emend®) |
|
|
Term
|
Definition
|
|
Term
|
Definition
Marinol®
Cannabinoid Derivative |
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
Drugs to Treat Hyperuricemia |
|
Definition
Allopurinol (Zyloprim®)
Febuxostat (Uloric®)
|
|
|
Term
|
Definition
Zyloprim®
Xanthine Oxidase Inhibitor |
|
|
Term
|
Definition
Uloric®
Xanthine Oxidase Inhibitor |
|
|
Term
Drugs Used with Chemotherapy |
|
Definition
Mesna (Mesnex®)
Leucovorin (Wellcovorin®)
|
|
|
Term
|
Definition
Mesnex®
Used with cyclophosphamide and ifosfamide to prevent hemorrhagic cystitis |
|
|
Term
|
Definition
Wellcovorin®
Used with 5-FU and Methotrexate
|
|
|